Epidemiological characteristics and risk factors of hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 9-10, 1997, Pages

  Chen, Chien Jen ^a   Yu, Ming Whei ^a   Liaw, Yun Fan ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Aetiology; Epidemiology; Gene environment interaction; Hepatocellular carcinoma

Indexed keywords

AFLATOXIN; ALCOHOL; ANABOLIC AGENT; ARSENIC; GLUTATHIONE TRANSFERASE; IRON; ORAL CONTRACEPTIVE AGENT; RETINOL; TESTOSTERONE; THORIUM DIOXIDE;

CANCER RISK; CONFERENCE PAPER; ETHNIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HEPATITIS VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

EID: 0030785082     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00513.x     Document Type: Conference Paper

References (118)

1. Bosch FX, Munoz N. Epidemiology of hepatocellular carcinoma. In: Bannsch P, Keppler D, Weber G, eds. Liver cell carcinoma. Dordrecht: Kluwer Academic, 1989; 3-12.
2. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J. Cancer Incidence in Five Continents, vol. VI. Lyon: International Agency for Research on Cancer, 1992; 930-1.
3. Lin TM, Tsu WT, Chen CJ. Mortality of hepatoma and cirrhosis of liver in Taiwan. Br. J. Cancer 1986; 54: 969-76.
4. Waterhouse J, Muir C, Shanmugaratnam K et al. Cancer Incidence in Five Continents, vol. III. Lyon: International Agency for Research on Cancer, 1976; 453-547.
5. Waterhouse J, Muir C, Shanmugaratnam K et al. Cancer Incidence in Five Continents, vol. IV. Lyon: International Agency for Research on Cancer, 1982; 671-789.
6. Muir C, Waterhouse J, Mack T et al. Cancer Incidence in Five Continents, vol. V. Lyon: International Agency for Research on Cancer, 1987; 796-939.
7. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res. 1987; 47: 4967-72.
8. Bartoloni St Omer F, Giannini A, Napoli P. Hepatocellular carcinoma and cirrhosis: A review of their relative incidence in a 25-year period in the Florence area. Hepatogastroenterology 1984; 31: 215-17.
9. Mant JWF, Vessey MP. Trends in mortality from primary liver cancer in England and Wales 1975-92: Influence of oral contraceptives. Br. J. Cancer 1995; 72: 800-3.
10. Yu MW, Tsai SF, Hsu KH et al. Epidemiologie characteristics of malignant neoplasms in Taiwan II. Liver cancer. J. Natl Public Health Assoc. (ROC) 1988; 8: 125-38.
11. Yu MW, Chen CJ. Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit. Rev. Oncol. Hematol. 1994; 17: 71-91.
12. London WT, McGlynn KA. Liver cancer. In: Schottenfeld D, Fraumeni F Jr, eds. Cancer: Epidemiology and Prevention, 2nd edn. New York: Oxford University Press, 1996; 772-93.
13. Beasley RP. Hepatitis B virus: The major etiology of hepatocellular carcinoma. Cancer 1985; 61: 1942-56.
14. Chen CJ, Yu MW, Wang CJ, Huang HY, Lin WC. Multiple risk factors of hepatocellular carcinoma: A cohort study of 1737 male adults in Taiwan. J. Gastroenterol. Hepatol. 1993; 8: S83-7.
15. Lu SN, Lin TM, Chen CJ et al. A case-control study of primary hepatocellular carcinoma in Taiwan. Cancer 1988; 62: 2051-5.
16. Chen CJ, Liang KY, Chang AS et al. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency of hepatocellular carcinoma. Hepatology 1991; 13: 398-406.
17. Chung WK, Sun HS, Park DH, Minuk GY, Hoofnagle JH. Primary hepatocellular carcinoma and hepatitis B virus in Korea. J. Med. Virol. 1983; 11: 99-104.
18. Lam KC, Yu MC, Leung JWC, Henderson BE. Hepatitis B virus and cigarette smoking: Risk factors for hepatocellular carcinoma in Hong Kong. Cancer Res. 1982; 42: 5246-8.
19. Yeh FS, Mo CC, Luo S, Henderson BE, Tong MJ, Yu MC. A serological case-control study of primary hepatocellular carcinoma in Guanxi, China. Cancer Res. 1985; 45: 872-3.
20. Trichopoulos D, Day NE, Kaklamani E et al. Hepatitis B virus, tobacco smoking and ethanol consumption in the etiology of hepatocellular carcinoma. Int. J. Cancer 1987; 39: 45-9.
21. Prince AM, Szmuness W, Michon J, Demaille J. A case-control study of association between primary liver cancer and hepatitis B infection in Senegal. Int. J. Cancer 1975; 16: 376-83.
22. Lingao AL, Domingo EO, Nishioka K. Hepatitis B virus profile of hepatocellular carcinoma in the Philippines. Cancer 1981; 48: 1590-5.
23. Tsukuma H, Hiyama T, Oshima A et al. A case-control study of hepatocellular carcinoma in Osaka, Japan. Int. J. Cancer 1990; 45: 231-6.
24. Tokudome S, Ikeda M, Matsushita K et at. Hepatocellular carcinoma among HBsAg positive blood donors in Fukuoka, Japan. Eur. J. Cancer Clin. Oncol. 1988; 24: 235-9.
25. Oshima A, Tsukuma H, Hiyama T, Fujimoto I, Yamano H, Tanaka M. Follow-up study of HBsAg-positive blood donors with special reference to effect of drinking and smoking on development of liver cancer. Int. J. Cancer 1984; 34: 775-9.
26. Vall Mayans M, Calvet X, Bruix J et al. Risk factors for hepatocellular carcinoma in Catalonia, Spain. Int. J. Cancer 1990; 46: 378-81.
27. Watanabe Y, Harada S, Saito I, Miymura T. Prevalence of antibody against the core protein of hepatitis C virus in patients with hepatocellular carcinoma. Int. J. Cancer 1991; 48: 340-3.
28. Tanaka K, Hirohata T, Koga S et al. Hepatitis C and hepatitis B in the etiology of hepatocellular carcinoma in the Japanese population. Cancer Res. 1991; 51: 2842-7.
29. Hasan F, Jeffers LJ, De Medina M et al. Hepatitis C-associated hepatocellular carcinoma. Hepatology 1990; 12: 589-91.
30. Di Bisceglie AM, Order SE, Klein JL et al. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am. J. Gastroenterol. 1991; 86: 335-8.
31. Vargas V, Castells L, Esteban JI. High frequency of antibodies to the hepatitis C virus among patients with hepatocellular carcinoma. Ann. Intern. Med. 1990; 112: 232-3.
32. Bruix J, Barrera JM, Calvet X et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; ii: 1004-6.
33. Kew MC, Houghton M, Choo QL, Kuo G. Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet 1990; 335: 873-4.
34. Chen DS, Kuo GC, Sung JL et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: The Taiwan Experience. J. Infect. Dis. 1990; 162: 817-22.
35. Chuang WL, Chang WY, Lu SN et al. The role of hepatitis B and C viruses in hepatocellular carcinoma in hepatitis B endemic area: A case-control study. Cancer 1992; 69: 2052-4.
36. Yu MW, You SL, Chang AS, Lu SN, Liaw YF, Chen CJ. Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan. Cancer Res. 1991; 51: 5621-5.
37. Zavitsanos X, Hatzakis A, Kaklamani E et al. Association between hepatitis C virus and hepatocellular carcinoma using assays based on structural and nonstructural hepatitis C virus peptides. Cancer Res. 1992; 52: 5364-7.
38. Coursaget P, Leboulleux D, Le Cann P, Bao O, Coll-Seck AM. Hepatitis C virus infection in cirrhosis and primary hepatocellular carcinoma in Senegal. Trans. R. Soc. Trop. Med. Hygiene 1992; 86: 552-3.
39. Dazza M, Meneses LV, Girard P et al. Absence of a relationship between antibodies to hepatitis C virus and hepatocellular carcinoma in Mozambique. Am. J. Trop. Med. Hygiene 1993; 48: 237-42.
40. Tsai JF, Jeng JE, Ho MS, Chang WY, Lin ZY, Tsai JH. Hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Chinese: A case-control study. Int. J. Cancer 1994; 56: 619-21.
41. Sun CA, Farzadegan H, You SL et al. Mutual confounding and interactive effects between hepatitis C and hepatitis B viral infections in hepatocellular carcinogenesis: A population-based case-control study in Taiwan. Cancer Epidemiol. Biomark. Prev. 1996; 5: 173-8.
42. Chang CC, Yu MW, Lu CF, Yang CS, Chen CJ. A nested case-control study on association between hepatitis C virus antibodies and primary liver cancer in a cohort of 9775 men in Taiwan. J. Med. Virol. 1994; 43: 276-80.
43. Yu MC, Tong MJ, Coursaget P, Ross RK, Govindarajan S, Henderson BE. Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. J. Natl Cancer Inst. 1990; 82: 1038-41.
44. Kalamani E, Trichopoulos D, Tzonou A et al. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA 1991; 265: 1974-6.
45. Stroffolini T, Chiaramonte M, Tiribelli C et al. Hepatitis C virus infection, HBsAg carrier state and hepatocellular carcinoma: Relative risk and population attributable risk from a case-control study in Italy. J. Hepatol. 1992; 16: 360-3.
46. Cordier S, Le Thi Bich Thuy, Verger P et al. Viral infection and chemical exposures as risk factors for hepatocellular carcinoma in Vietnam. Int. J. Cancer 1993; 55: 196-201.
47. Tanaka K, Ikematsu H, Hirohata T, Kashiwagi S. Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: Possible role of type Ib (II) infection. J. Natl Cancer Inst. 1996; 88: 742-6.
48. Van Rensburg SJ, Cook-Mozaffari P, Van Schalkwyk DJ, Van Der Watt JJ, Vincent TJ, Purchase IF. Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br. J. Cancer 1985; 51: 713-26.
49. Peers F, Bosch X, Kaldor J, Linsell A, Pluijman M. Aflatoxin exposure, hepatitis B virus infection and liver cancer in Swaziland, Int. J. Cancer 1987; 39: 545-53.
50. Autrup H, Seremet T, Wakhisi J, Wasunna A. Aflatoxin exposure measured by urinary excretion of aflatoxin B1-guanine adduct and hepatitis B virus infection in areas with different liver cancer incidence in Kenya. Cancer Res. 1987; 47: 3430-3.
51. Yeh FS, Yu MC, Mo CC, Luo S, Tong MJ, Henderson BE. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China, Cancer Res. 1989; 49: 2506-9.
52. Campbell TC, Chen J, Liu C, Parpia B. Nonassociation of aflatoxin with primary liver cancer in a cross-sectional ecological survey in the People's Republic of China. Cancer Res. 1990; 50: 6882-93.
53. Ross RK, Yuan JM, Yu MC et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992; 339: 943-6.
54. Hatch MC, Chen CJ, Levin B et al. Urinary aflatoxin levels, hepatitis-B virus infection and hepatocellular carcinoma in Taiwan, Int. J. Cancer 1993; 54: 931-4.
55. Chen CJ, Wang LY, Lu SN et al. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 1996; 24: 38-42.
56. Wang LY, Hatch M, Chen CJ et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int. J. Cancer 1996; 67: 620-5.
57. Chen CJ, Yu MW, Liaw YF et al. Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma. Am. J. Hum. Genet. 1996; 59: 128-34.
58. Tu J, Gao R, Zhang D et al. Hepatitis B virus and primary liver cancer on Chongming Island, People's Republic of China. Natl Cancer Inst. Monogr. 1985; 69: 213-15.
59. Hirayama T. A large-scale cohort study on risk factors for primary liver cancer, with special reference to the role of cigarette smoking. Cancer Chemother. Pharmacol. 1989; 23: S114-17.
60. Goodman MT, Moriwaki H, Vaeth M, Akiba S, Hayabuchi H, Mabuchi K. Prospective cohort study of risk factors for primary liver cancer in Hiroshima and Nagasaki, Japan. Epidemiology 1995; 6: 36-41.
61. Kono S, Ikeda M, Tokudome S, Nishizumi M, Kuratsune M. Cigarette smoking, alcohol and cancer mortality: A cohort study of male Japanese physicians. Jpn. J. Cancer Res. 1987; 78: 1323-8.
62. Shibata A, Hirohata T, Toshima H, Tashiro H. The role of drinking and cigarette smoking in the excess deaths from liver cancer. Jpn. J. Cancer Res. 1986; 77: 287-95.
63. Tanaka K, Hirohata T, Takeshita S. Blood transfusion, alcohol consumption, and cigarette smoking in causation of hepatocellular carcinoma: A case-control study in Fukuoka, Japan. Jpn. J. Cancer Res. 1988; 79: 1075-82.
64. Yu MC, Mack T, Hanisch R et al. Hepatitis, alcohol consumption, cigarette smoking, and hepatocellular carcinoma in Los Angeles. Cancer Res. 1983; 43: 6077-9.
65. Yu MC, Harris R, Kabat G et al. Cigarette smoking, alcohol consumption and primary liver cancer: A case-control study in the USA. Int. J. Cancer 1988; 42: 325-8.
66. Austin H, Delzell E, Grufferman S et al. A case-control study of hepatocellular carcinoma and the hepatitis B virus, cigarette smoking, and alcohol consumption. Cancer Res. 1986; 46: 962-6.
67. Stemhagen A, Slade J, Altman R, Bill J. Occupational risk factors and liver cancer: A retrospective case-control study of primary liver cancer in New Jersey. Am. J. Epidennol. 1983; 117: 443-54.
68. Trichopoulos D, MacMahon B, Sparros L, Merikas G. Smoking and hepatitis B-negative primary hepatocellular carcinoma. J. Natl Cancer Inst. 1980; 65: 111-14.
69. La Vecchia C, Engri E, Decarli A, D'Avanzo B, Franceschi S. Risk factors for hepatocellular carcinoma in northern Italy. Int. J. Cancer 1988; 42: 872-6.
70. Filippazzo MG, Aragona E, Cottone M et al. Assessment of some risk factors for hepatocellular carcinoma: A case control study. Stat. Med. 1985; 4: 345-51.
71. Hardell L, Bengtsson NO, Jonsson U, Eriksson S, Larsson LG. Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria: An epidemiological investigation. Br. J. Cancer 1984; 50: 389-97.
72. Kew MC, Di Bisceglic AM, Paterson AC. Smoking as a risk factor in hepatocellular carcinoma: A case-control study in southern African blacks. Cancer 1985; 56: 2315-17.
73. Yu MW, Hsieh HH, Pan WH, Yang CS, Chen CJ. Vegetable consumption, serum retinol level, and risk of hepatocellular carcinoma. Cancer Res. 1995; 55: 1301-5.
74. Chen CJ, Lin LJ. Human carcinogenicity and atherogenicity induced by chronic exposure to inorganic arsenic. In: Nriagu O, ed. Arsenic in the Environment, Part II: Human Health and Ecosystem Effects. New York: John Wiley & Sons Inc, 1994; 109-31.
75. Chen CJ, Wu NM, Lee SS, Wang JD, Cheng SH, Wu HY. Atherogenicity and carcinogenicity of high-arsenic artesian well water: Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis 1988; 8: 452-60.
76. Chen CJ, Chuang YC, Lin TM, Wu HY. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: High-arsenic artesian well water and cancers. Cancer Res. 1985; 45: 5895-9.
77. Chen CJ, Kuo TL, Wu NM. Arsenic and cancers. Lancet 1988; i: 414-15.
78. Chen CJ, Wang CJ. Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res. 1990; 50: 5470-4.
79. Chen CJ, Chen CW, Wu MM, Kuo TL. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br. J. Cancer 1922; 66: 888-92.
80. Lu SN, Chen CJ. Prevalence of hepatitis B surface antigen carrier status among residents in the endemic area of chronic arsenicism in Taiwan. Anticancer Res. 1991; 11: 229-34.
81. National Academy of Sciences, Committee on the Biological Effects of Ionizing Radiation. The effects on populations of exposure to low levels of ionizing radiation. Washington, DC: National Academy of Sciences, 1980.
82. Kato I, Kido C. Increased risk of death in thorotrast-exposed patients during the late follow-up period. Jpn. J. Cancer Res. 1987; 78: 1187-92.
83. Van Kaick G, Wesch H, Luhrs H et al. Radiation-induced primary liver tumors in "thorotrast patients". Recent Results Cancer Res. 1986; 100: 16-22.
84. Forman D, Bennett B, Stafford J et al. Exposure to vinyl chloride and angiosarcoma of the liver: A report of the register of cases. Br. J. Indust. Med. 1985; 42: 750-3.
85. Evans D, Williams W, Kung I. Angiosarcoma and hepatocellular carcinoma in vinyl chloride workers. Histopathology 1983; 7: 377-88.
86. Prieto J, Barry M, Sherlock S. Serum ferritin in patients with iron overload and with acute and chronic liver diseases. Gastroenterology 1975; 68: 525-33.
87. Blumberg RS, Chopra S, Ibrahim R et al. Primary hepatocellular carcinoma in idiopathic hematochromatosis after reversal of cirrhosis. Gastroenterology 1988; 95: 1399-402.
88. Neuberger J, Forman D, Doll R, Williams R. Oral contraceptives and hepatocellular carcinoma. BMJ 1986; 292: 1355-7.
89. Palmer JR, Rosenberg L, Kaufman DW, Warshauer ME, Stolley P, Shapiro S. Oral contraceptive use and liver cancer. Am. J. Epidemiol. 1989; 130: 878-82.
90. Yu MC, Tong MJ, Govindarahan S, Henderson BE. Non-viral risk factors for hepatocellular carcinoma in a low risk population, the non-Asians of Los Angeles County, California. J. Natl Cancer Inst. 1991; 83: 1820-6.
91. Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C. Female hormone utilization and risk of hepatocellular carcinoma. Br. J. Cancer 1993; 67: 635-7.
92. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Combined oral contraceptives and liver cancer. Int. J. Cancer 1989; 43: 254-9.
93. Kew MC, Song E, Mohammed A, Hodkinson J. Contraceptive steroids as a risk factor for hepatocellular carcinoma: A case-control study in South African black women. Hepatology 1990; 11: 298-302.
94. Mokrohisky S, Ambruso D, Hathaway W. Fulminant hepatic neoplasia after androgen therapy. N. Engl. J. Med. 1977; 296: 1411-12.
95. Yu MW, Chen CJ. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res. 1993; 53: 790-4.
96. Yuan JM, Ross RK, Stanczyk FZ et al A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China. Int. J. Cancer 1995; 63: 491-3.
97. Bengtsson NO, Hardell L. Porphyrias, porphyrins and hepatocellular cancer. Br. J. Cancer 1986; 54: 115-17.
98. Sizaret P, Clerc M, Esteve J et al. M2 alpha-1-antitrypsin phenotype and primary liver cancer. Br. J. Cancer 1981; 43: 226-8.
99. La Vecchia C, Negri E, D'Avanzo B et al. Medical history and primary liver cancer. Cancer Res. 1990; 50: 6274-7.
100. Kew MC, McKnight A, Hodkinson J et al. The role of membranous obstruction of the inferior vena cava in the etiology of hepatocellular carcinoma in southern African blacks. Hepatology 1989; 9: 121-5.
101. Yang P, Buetow KH, Lustbader ED et al. Evidence for a major locus modifying risk for primary hepatocellular carcinoma. Am. J. Hum. Genet. 1990; 47: A25.
102. Shen FM, Lee MK, Gong HM et al. Complex segregation analysis of primary hepatocellular carcinoma in Chinese families: Interaction of inherited susceptibility and hepatitis B viral infection. Am. J. Hum. Genet. 1991; 49: 88-93.
103. Huang KL. Familial aggregation study of hepatocellular carcinoma in the Penghu Islets. Masters thesis, Graduate Institute of Public Health, National Taiwan University, Taipei, Taiwan. 1994.
104. Yu MW, Gladek-Yarborough A, Chiamprasert S, Santella RM, Liaw YF, Chen CJ. Cvtochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology 1995; 109: 1266-73.
105. Agundez JAG, Olivera M, Ladero JM et al. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics 1996; 6: 501-12.
106. Hsieh LL, Huang RC, Yu MW, Chen CJ, Liaw YF. L-myc, GST M1 genetic polymorphism and hepato-cellular carcinoma risk among chronic hepatitis B carriers. Cancer Lett. 1996; 103: 171-6.
107. Hsu IC, Metcalf RA, Sun T et al. Mutational hotspot in the p53 gene in human hepatocellular carcinoma. Nature 1991; 350: 427-8.
108. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429-31.
109. Yu MW, Chen CJ, Luo JC, Brandt-Rauf PW, Carney WP, Santella RM. Correlations of chronic hepatitis B virus infection and cigarette smoking with elevated expression of neu oncoprotein in the development of hepatocellular carcinoma. Cancer Res. 1994; 54: 5106-10.
110. Wang LY, Huang SJ, Liaw YF, Chen CJ. Increased sister chromatid exchange frequency in peripheral lymphocytes of hepatocellular carcinoma patients. J. Gastroenterol. Hepatol. 1993; 8: S119-22.
111. Simon D, London T, Hann HL, Knowles BB. Chromosome abnormalities in peripheral blood cells of hepatitis B virus chronic carriers. Cancer Res. 1991; 51: 6176-9.
112. Buetow KH, Murray JC, Israel JL et al. Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma. Proc. Natl Acad. Sci. USA 1989; 86: 8852-6.
113. Zhang W, Hirohaski S, Tsuda H et al. Frequent loss of heterozygosity on chromosomes 16 and 4 in human hepatocellular carcinoma. Jpn. J. Cancer Res. 1990; 81: 108-11.
114. Fujimori M, Tokino T, Hino O et al. Allelotype study of primary hepatocellular carcinoma. Cancer Res. 1991; 51: 89-93.
115. Beasley RP. Hepatitis B virus as the etiologic agent in hepatocellular carcinoma: Epidemiologic considerations. Hepatology 1982; 2: S21-6.
116. Chen DS. Hepatitis B virus infection, its sequelae, and prevention in Taiwan. In: Okuda K, Ishak G, eds. Neoplasm of the Liver. Tokyo: Springer-Verlag, 1980; 71-80.
117. Liaw YF, Tai DI, Chu CM et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. Gastroenterology 1986; 90: 263-7.
118. Tsukuma H, Hiyama T, Tanaka S et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med. 1993; 328: 1797-801.